Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial

Abstract Purpose: Pre-clinical data suggests that ceralasertib, a potent ATR inhibitor, might reverse resistance to anti-PD-(L)1 in KRAS mutant lung adenocarcinoma (LUAD). Activity of ceralasertib/durvalumab was, therefore, assessed in two prospective, parallel immune checkpoint blockade (ICB)-resistant cohorts, one harbouring KRAS mutations (J1), the other without (NAJ), within the National Lung Matrix Trial. Methods: Oral ceralasertib was administered (240 mg twice daily on days 15-28) with durvalumab (1500 mg IV, on day 1 of every 28-day cycle) until disease progression. Co-primary outcomes were objective response (OR) and 24-week durable clinical benefit (DCB). Biological impacts of ceralasertib were assessed in a human BJ-hTERT KRASV12ER-TAM model. Immunological impact of KRAS mutation was assessed using gene-level processed LUAD TCGA PanCancer data. Results: Between 02-Jul-2020 and 31-Oct-2021, 43 patients were registered; 19 and 18 of whom were evaluable for outcome analysis in cohorts J1 and NAJ, respectively. Cohort target recruitment (30 participants each) was not reached due to trial closure at the pre-planned end of funding. Bayesian estimates of DCB rates (95% credible intervals) were 37.7% (19.1-59.2) for J1 and 29.3% (12.6-51.2) for NAJ. Two participants demonstrated OR, both KRAS mutant, one of whom had KEAP1/STK11 co-mutation. KRAS mutation significantly increased the proportion of cells harbouring ceralasertib-induced micronuclei. Ceralasertib blunted KRAS-mediated STAT1 downregulation. Conclusion: Whilst outcome measures on ceralasertib/durvalumab in anti-PD-(L)1 resistant LUAD patients are modestly higher in KRAS mutant participants, these differences are not significant, a result likely related to the modest impact of KRAS mutation alone on the immunobiology of LUAD.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-09-09
DOI
https://doi.org/10.1158/1078-0432.ccr-26-1365
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial

Mary O’Brien, Lucinda Jane Billingham, Elizabeth Toy, Claire Wilson et al.
Clinical Cancer Research
Lung Cancer Treatments and Mutations
article

Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial

Mary O’Brien, Lucinda Jane Billingham, Elizabeth Toy, Claire Wilson, Joshua Savage, Nicholas Anthony Coupe, Charles Swanton, Alastair Greystoke, Manita Mehmi, K. Clarke, Heather M. Long, James Spicer, Gary Middleton, Aditi Kanhere, Adam Dangoor, Andrew D. Beggs, Eva Petermann, Sanjay Popat, Luke Ames, Helen L. Robbins, Timothy Anthony Yap, Sarah Danson, Richard D. Kelly, Martin Förster, Judith Cave, Pooja Jain, D. Muthukumar, RJ Wilkins, Gillian Price, Richard Buchanan, Yvonne Summers, David Gilligan, Paul Shaw, Nicola Steele, Joe De La Mata Chicharro
article en

Abstract

Abstract Purpose: Pre-clinical data suggests that ceralasertib, a potent ATR inhibitor, might reverse resistance to anti-PD-(L)1 in KRAS mutant lung adenocarcinoma (LUAD). Activity of ceralasertib/durvalumab was, therefore, assessed in two prospective, parallel immune checkpoint blockade (ICB)-resistant cohorts, one harbouring KRAS mutations (J1), the other without (NAJ), within the National Lung Matrix Trial. Methods: Oral ceralasertib was administered (240 mg twice daily on days 15-28) with durvalumab (1500 mg IV, on day 1 of every 28-day cycle) until disease progression. Co-primary outcomes were objective response (OR) and 24-week durable clinical benefit (DCB). Biological impacts of ceralasertib were assessed in a human BJ-hTERT KRASV12ER-TAM model. Immunological impact of KRAS mutation was assessed using gene-level processed LUAD TCGA PanCancer data. Results: Between 02-Jul-2020 and 31-Oct-2021, 43 patients were registered; 19 and 18 of whom were evaluable for outcome analysis in cohorts J1 and NAJ, respectively. Cohort target recruitment (30 participants each) was not reached due to trial closure at the pre-planned end of funding. Bayesian estimates of DCB rates (95% credible intervals) were 37.7% (19.1-59.2) for J1 and 29.3% (12.6-51.2) for NAJ. Two participants demonstrated OR, both KRAS mutant, one of whom had KEAP1/STK11 co-mutation. KRAS mutation significantly increased the proportion of cells harbouring ceralasertib-induced micronuclei. Ceralasertib blunted KRAS-mediated STAT1 downregulation. Conclusion: Whilst outcome measures on ceralasertib/durvalumab in anti-PD-(L)1 resistant LUAD patients are modestly higher in KRAS mutant participants, these differences are not significant, a result likely related to the modest impact of KRAS mutation alone on the immunobiology of LUAD.

Clinical Cancer Research
Birmingham City University (GB), Royal Marsden NHS Foundation Trust (GB), The University of Texas MD Anderson Cancer Center (US), University of Liverpool (GB), King's College London (GB), Royal Devon & Exeter NHS Foundation Trust (GB), Beatson West of Scotland Cancer Centre (GB), Aberdeen Royal Infirmary (GB), The Francis Crick Institute (GB), St James's University Hospital (GB), At Bristol (GB), Cambridge University Hospitals NHS Foundation Trust (GB), University Hospital Southampton NHS Foundation Trust (GB), University College Birmingham (GB), University of Alabama at Birmingham (US), Manchester University NHS Foundation Trust (GB), Bristol Hospital (US), NIHR Bristol Biomedical Research Centre (GB), King's College School (GB), Colchester Hospital (GB), Royal Marsden Hospital (GB), West Midlands Police (GB), The London College (GB), Oxford University Hospitals NHS Trust (GB), Velindre Cancer Centre (GB), University College London (GB), University of Birmingham (GB), Newcastle University (GB), University of Sheffield (GB)
Openalex Percentile: Top 11%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.